Index of Articles From AIDS Treatment News
1998
- Issue #309, December 18, 1998
- Complementary Treatments: Dr. Kaiser's New Book
- AIDS Treatment News January Publication Schedule
- Buyers' Club List, December 1998
- AIDS Treatment News Index, 1998
Advertisement
- Issue #308, December 4, 1998
- Major Vaccine Project: Largest AIDS Research Grants Ever to Two "Most Promising" Approaches
- Disability and Returning to Work: Proposed Change to Let Disabled Keep Benefits
- Low-Dose Cyclosporin: Government Trial Recruiting, CD4 Count Over 500
- IDSA Conference: Abstracts on the Web
- 4th International Congress on Drug Therapy in HIV Infection: Summaries on Web
- New Drug Pricing: Progress on World AIDS Day?
- Issue #307, November 20, 1998
- GATT and the Gap: How to Save Lives
- Testosterone Cream and Gel Available; Prices Vary Greatly
- Urgent: Medicaid Rule Changes, Comments Due November 30
- Health Insurance: New NAPWA Guide
- Flu Season Protection: Information on Web
- Retroviruses Conference: Press Must Register by December 31 or Earlier
- Medical Marijuana Wins 7 of 7 U.S. Elections
- Northern California: HIV Advocacy Conference, December 12-13
- Free Newsletter Subscriptions Through Medical Practices, Clinics
- Issue #306, November 6, 1998
- T-20 Results Published
- U.S. Testosterone Shortage: Call for Information
- Abacavir (ZiagenTM) Approval Recommended
- Induction/Maintenance Strategy Failed in U.S., French Trials
- Efavirenz (SustivaTM) Available through Patient Assistance Program
- Amprenavir (AgeneraseTM) Submitted for Approval
- National AIDS Treatment Advocates Forum, December 5-8, Philadelphia
- Glasgow Conference Reports on Web
- Lipodystrophy, Anemia, Resistance, Other Articles at www.healthcg.org/hiv
- New TB Guidelines for Persons with HIV
- Alitretinoin Gel (Panretin®) FDA Hearing November 16
- Record AIDS Funding from Outgoing Congress
- Help Wanted, AIDS Treatment Writer, New York
- California: Medicaid Expansion Needs Quick Attention after the Election
- Youth Consent, Confidentiality for Counselors, San Francisco December 1
- California ADAP Update
- Issue #305, October 16, 1998
- Retroviruses Conference Scholarship Deadline Nov. 3
- AmFAR RFPs: Immune Reconstitution, HIV Vaccines; Grants $75,000 to $150,000, Letter Due November 4
- Oakland, California: October 22 Panel on Alternative Treatments
- Help Wanted, AIDS Treatment Writer, New York
- Nelfinavir (Viracept®) Price Increase 4.6%
- 11th National HIV/AIDS Update Conference; Abstract Deadline November 1
- Association of Nurses in AIDS Care, November 15-18, San Antonio
- San Francisco: Hepatitis C Community Forum, October 20
- Cannabis and Cannabidiol: Interview with Robert Gorter, M.D.
- California ADAP Alert
- Issue #304, October 2, 1998
- Efavirenz (SUSTIVATM) Approved
- Crixivan® (Indinavir): Three Doses Daily, Not Two, in Most Regimens
- Amprenavir (AgeneraseTM) Now Available in Expanded Access
- Successful Standard Treatment for Lipid Abnormalities: Experience with 44 Patients
- San Francisco: Body Shape Changes and Lipodystrophy -- Community Forum October 19
- ICAAC Conference: Daily Summaries Available
- Abacavir (ZiagenTM) Advisory Committee Meeting, November 2
- Prison Treatment Programs: Glaxo-Wellcome Awards 19 Grants
- Iscador Update: Interview with Robert Gorter, M.D.
- United States Conference on AIDS, Dallas, Oct. 29 - Nov. 1
- San Francisco: POZ Life Expo, October 16-17
- Issue #303, September 18, 1998
- Lipodystrophy Research Coordination Needed
- ICAAC Report, September 27, by Telephone Conference
- PMPA Trials Recruiting
- Improved Viral Load Test: Open Letter on FDA Approval
- Acupuncture Research Symposium, Sept. 26-27 at Stanford University
- Indigenous Nations AIDS Conference, Prior Lake, Minnesota, September 27-30
- Titillationism -- Or, Register Now to Vote!
- Issue #302, September 4, 1998
- Post-Exposure Prevention (PEP); What to Do If the Condom Breaks?
- New Drug Pricing Consensus Letter, Sign-Ons Requested
- Hepatitis C: New Treatment Overview
- HIV and Hepatitis Physician Education, San Francisco Sept. 12
- IHV 1998 Annual Meeting ("Gallo Lab Meeting"); Program, Many Talks on Web
- Fomivirsen Approved for CMV Retinitis: First Antisense Drug
- Prison Issues: National Conference, Web Sites
- Help Wanted: Executive Director, Project Inform
- Issue #301, August 21, 1998
- The CHORUS Database on Patient Clinical Care -- and Interview with Stephen Becker, M.D.
- Retroviruses Conference, Jan. 31 - Feb. 4, 1999, Chicago: Abstract Deadline October 1
- International Healthcare Resource Allocation Conference, November 15-18, Cancun, Mexico
- Herbal Medicine Safety Workshop, National Institutes of Health, Research Triangle Park, September 23 and 24
- Medical Marijuana: Strong Support in Oakland
- San Francisco: Forum on Body Composition Changes, September 1
- San Francisco: Intensive Seminar on Benefits, September 10-11
- Help Wanted: Assistant Director, Forum for Collaborative HIV Research
- Major Email Security Flaws Discovered: How to Protect Your Data
- Issue #300, August 7, 1998
- T-20: New Trial Enrolling, 9 U.S. Cities
- New Vaccine+HAART Treatment Trial Enrolling at NIH
- Ritonavir Capsule Manufacturing Problems Will Require Switch to Liquid Formulation
- Geneva Medical Report Now on Web
- Viral Load: Roche Applies for Marketing Approval for UltraSensitive Test
- IHV 1998 Annual Meeting (Gallo Lab Meeting) August 23-29 in Baltimore
- Geneva Update Town Hall Meeting, August 17, Redwood City, California
- San Francisco: Employment-Issues Training for Service Providers, August 19
- AIDS Meals and Nutrition Conference, September 10-13, San Francisco
- Rural AIDS Conference, Sept. 10-12, Albuquerque
- Hepatitis C Conference, August 23-25 in Oakland
- Medical Marijuana: Healing Alternatives Begins Distribution
- Nutritional Supplements: Call for Information
- Issue #299, July 17, 1998
- Efavirenz (Sustiva) May Equal or Exceed Protease Inhibitor in Initial Antiretroviral Combination
- Viral Resistance Overview
- Fusion inhibitors, T-20; Chemokine Variants; Tat and Interferon Antibodies: Gallo Describes Three New Treatment Approaches
- Geneva Conference: Finding Information on the Web and Elsewhere
- AIDS Diarrhea: Phase III Trial Recruiting in Over 30 U.S. Sites
- San Francisco: Geneva Conference Review, July 22
- Issue #298, July 10, 1998
- HIV-Specific Immune Responses Restored by HIV Immunogen Plus Antiretroviral Suppression
- Successful Treatment of "Buffalo Hump" with Growth
Hormone
- Geneva Conference Treatment Highlights
- AIDS Treatment News Internet Directory
- Women's Treatment Information and Advocacy: Position at Project Inform
- San Francisco, Oakland: Treatment Access and Information Workshop, July 24, July 31, or August 14
- Scientific American July Special Report on AIDS
- Issue #297, June 22, 1998
- Agouron and Immune Response to Commercialize Remune Immune-Based Treatment
- 12th World AIDS Conference, Geneva, June 28 - July 3: How to Participate from Home
- Geneva Arrangements (If You Are Going)
- Metabolic Complications, Growth Hormone Treatment: New Studies Planned
- Ribavirin Approved for Hepatitis C Combination Treatment
- Pediatric HIV Treatment: Federal Guidelines Discussed July 22
- Congress: How You Can Help
- San Francisco: Six-Week Workshop on Returning to Work
- Issue #296, June 5, 1998
- New Guide to Living with HIV Infection
- Medical Marijuana: Largest Provider Closed, Some Alternatives Available
- Medical Marijuana Distribution Summit, Sacramento: Video Available
- Efavirenz (Sustiva, DMP 266) and Saquinavir (Fortovase®) Combination: Pharmacologic Interaction
- If You Are Exposed to HIV: Guidelines Published for Postexposure Prevention
- Medical Marijuana Study in San Francisco: Pays $1000, 25 Days in Hospital
- Acetylcarnitine and Neuropathy: Call for Information
- Prison or Discharge Treatment Programs: Funding Available, Proposals Due June 29
- Correction: Hepatitis C Trial
- Email Experts; Librarians: AIDS Treatment News Seeks Expert Advice
- Prospective Case Series in Clinical Trial Design -- Proposal, and NTZ Example
- Issue #295, May 15, 1998
- Hepatitis C Important Treatment Advance: Interview with Douglas Dieterich, M.D.
- Hepatitis C and HIV: Ribavirin Plus Interferon Study Recruiting
- Metabolic Changes: Concerns About Heart, Circulatory Risks
- NTZ: Advisory Committee Votes Against Approval
- Update on AIDS Wasting and Lipodystrophy: One-Day Seminar in Geneva, June 28
- Geneva Conference: Call for Alternative and Traditional Healing Practices Material
- AIDS Vaccine: Major Report Available
- Issue #294, May 1, 1998
- VIAGRA Warning re "Poppers" and Notice re Protease Inhibitors
- Preventing Mother-Infant Transmission Worldwide: What Is Needed? Interview with Joseph Saba, M.D.
- HIV Treatment Options
- Community Organizing by Email: Needle Exchange Mobilization Example
- 15th Annual Candlelight March, May 17
- San Francisco: Healing Alternatives Opens Castro Office
- Issue #293, April 17, 1998
- T-20 and Trimeris
- Adefovir Dipivoxil (PREVEON) Improved Expanded-Access Program
- Adefovir Dipivoxil (PREVEON) New Results with Hepatitis B, HIV
- HIV/AIDS Nutrition Book for Clinicians
- Treatment Conference Call May 2
- Geneva Conference Communication Proposals for Minorities Due May 12
- New Priority Email Delivery from AIDS Treatment News
- Issue #292, April 3, 1998
- AIDS Survival: Major Improvement Documented
- Fatigue and HIV: Interview with Lisa Capaldini, M.D. Part II
- Nevirapine: One-Year Combination Results Published
- Notice on Efavirenz and Pregnancy
- AIDSWatch May 3-5 in Washington
- Medical Marijuana: Time to Contact Your U.S. Representative
- California AIDS Lobby Day, April 20 in Sacramento
- Issue #291, March 20, 1998
- Future Directions
- Fatigue and HIV: Interview with Lisa Capaldini, M.D.
- 1592 (Abacavir, or New Name Ziagen) More Widely Available March 23
- CD4 Increase Despite Protease Inhibitor "Failure" in Swiss Study
- March 25 Free Telephone Conference, "Choosing the Right HIV Treatment Strategy"
- Women's HIV Treatment Workshop, Oakland, California, March 28
- New FDA Commissioner Nomination Soon?
- Issue #290, March 6, 1998
- Drug Interactions: Resources for Patients and Professionals
- Medical Marijuana Update:
- Medical Advances with International Impact:
Oral Contraceptive / Nevirapine Interaction Trial, New York and San Francisco
IL-2 Without Antiretroviral Therapy, Trial Near Washington D.C.
FDA Publishes Conflict of Interest Rules for Clinical Trials
Issue #289, February 20, 1998
- Clinical Implications of Virological "Failure":
Interview with Steven Deeks, M.D., San Francisco General
Hospital
- Retroviruses Conference Notes
- Retroviruses Conference: For More Information
- Opportunistic Infections: Major New Report
Issue #288, February 6, 1998
- Organ Transplants: Interview with Jeff Getty, on Ending the
Exclusion of People with HIV
- HIV/AIDS in Prison Project Threatened: Interview with Judy
Greenspan, Director
- 5th Retroviruses Conference in Chicago
- Adefovir Dipivoxil (PREVEON): Expanded Access
Restrictions Being Eased
- NTZ Submitted to FDA for Cryptosporidiosis
Issue #287, January 23, 1998
- Marijuana, Inflammation, and CT-3 (DMH-11C): Cannabis Leads to New Class of Anti-inflammatory Drugs
- Medical Marijuana: Federal, State Attacks Against California Cannabis Clubs
- Medical Marijuana: The Will Foster Case in Oklahoma
- Micronutrients and the HIV Patient, March 23-24 in Boston
- Scholarships Available for Geneva Conference: Application Deadline March 8
- More Attention to HIV Reporting As GMHC Changes Policy
Issue #286, January 9, 1998
- 1998 Outlook: Treatment, Research, Access
- Efavirenz (Sustiva) Expanded Access Now to 400 CD4
- San Francisco: Blood Needed for HIV Immunology Studies
- Treatment Conferences and Meetings, 1998
1997
- Issue #285, December 19, 1997
- New Approaches to HIV Treatment: Interview with Robert Gallo, M.D.
- 1592 (Abacavir): Do Not Rechallenge After Hypersensitivity Reaction
- Adefovir Dipivoxil (PREVEON) Expanded Access Begins
- San Francisco: Eviction Legislation Protects Some with Major Illness
- New York: One-Day Treatment Information Forum, January 17
- AIDS Treatment News Index, 1997
- Issue #284, December 5, 1997
- Viral Immunology Advances Suggest Treatment Strategies
- New Meeting on Immune Surrogate Markers, Baltimore, January 9-11
- FDA Approves New Kind of Lymphoma Treatment
- Major AIDS Institute Inaugurated in San Francisco
- Protease Inhibitor Information: FDA Fact Sheet Available
- Protease Inhibitor Failure Trial: Combination 1592, 141W94, and Efavirenz
- New AIDS Bookstore on World Wide Web
- Revised Federal Antiretroviral Treatment Guidelines
- FDA Reform Signed into Law
- Press Must Register Now to Cover February Retroviruses Meeting; December 29 Deadline
- Correction: FORTOVASE Information Number for Patients in Washington D.C. Area
- December Deadline for Charitable Giving and Tax Relief
- Issue #283, November 21, 1997
- FortovaseTM Approved: New Saquinavir Formulation
- 1592 Access: Larger Program Planned
- HIV Resistance Testing: More Questions Than Answers
- Drug-Resistant Herpes: Cidofovir Gel in Limbo. Interview with
Jay Lalezari, M.D.
- Treatment in Developing Countries: New UNAIDS Pilot Program
- Geneva Conference Deadlines: Time to Start Planning
- Issue #282, November 7, 1997
- HIV Research Overview: Interview with David Ho, M.D.
- Expanded Access to Experimental Drugs: Activists Seek More Open Programs
- AIDS Dementia: 1592 Now More Available
- Qigong Exercise Program Airing in Los Angeles, Orange County; Tape Available
- Correction: ICAAC Location
- AIDS Service Organizations: Accountability Issue Surfaces in San Francisco
- Issue #281, October 17, 1997
- ICAAC Newspaper Headlines Misleading on Protease Inhibitor Failure
- ICAAC: Online Summaries Available
- Long-Term Strategies: Should Some Patients Wait to Start Protease Inhibitors? -- Interview with Keith Henry, M.D.
- Delavirdine Combination and Viral Load
- Linezolid, New Antibiotic Studied for MRSA, Available for Compassionate Use
- International Conference on AIDS Wasting, Nov. 16-19, Fort Lauderdale, FL
- Telephone Conference on Resistance and Cross-Resistance, Nov. 5, 1997
- Telephone Conference on HIV Treatment Developments, Oct. 30
- Money, Foundations, and the Public Agenda: Investigative Articles Available
- Issue #280, October 3, 1997
- Fifty Volunteer for Live-Vaccine Trial
- 37th ICAAC Conference, Toronto, Sept. 28 - Oct. 1
- Unused Drugs Sought for Donation Abroad
- Pregnant Women Eligible for Single-Dose Nevirapine
Study
- ADAP, Research, and Prevention Funding, and Needle
Exchange,
Facing Decisions Now in Congress: Your Calls Important
- "Poppers"--Annotated Reference List
Available
- HMOs and Quality Care for HIV -- Interview with Stephen
Becker, M.D. (Part 2)
- Issue #279, September 19, 1997
- Engineered Virus Targets HIV-Infected Cells: Interview with Garry Nolan, Ph.D.
- Efavirenz (SUSTIVATM) Expanded Access Begins October 1
- Efavirenz (SUSTIVATM), Formerly DMP-266) 48-Week Data Announced
- T-20: Entirely New Antiretroviral
- IDSA '97: Conference Without Activists
- IDSA '97: What It Did Right
- IDSA '97: Excellent Medical Summaries on Tape
- Issue #278, September 5, 1997
- HMOs and Quality Care for HIV -- Interview with Stephen Becker, M.D.
- Retroviruses Conferences Deadlines: Community Press and Scholarships November 3; Abstracts October 3; Late-Breaker January 5
- DMP 266 Trials Recruiting, Many Cities -- Protease Inhibitor Naive
- Adefovir Dipivoxil Trials: CD4 100-500, Protease Inhibitor Naive
- Activism: Internet; San Francisco Workshop; Needle Exchange September 17; California Prison HIV Care
- Virologic Failure; Managed Care; Treatment Rejectionists; Medical Research: GLMA Achievement Award Address
- Issue #277, August 15, 1997
- Protease Inhibitors' Metabolic Side Effects
- Taxol Approved for Kaposi's Sarcoma
- San Francisco: Changes at Conant Medical Group
- IDSA Annual Meeting, September 12-16, San Francisco
- 1998 Retroviruses Conference: Deadlines Available Soon
- AIDS Treatment News Must Increase Prices
- Consensus Letter: Peter Duesberg
- Issue #276, August 1, 1997
- 1592 Adult Compassionate-Use Program Announced
- Returning to Work: Articles on Social
Security Rules
- Federal AIDS Policy Issues Today
- Issue #275, July 18, 1997
- Health Insurance More Available:
Federal Legislation Effective July 1
- Pediatric Trial of 141W94, Vertex
Protease Inhibitor
- Pediatric 1592 Compassionate Use
Program Begins
- World Wide Web AIDS Medical Information
- Issue #274, July 4, 1997
- New Standard of Care for HIV Disease
- Major Pediatric Study Stopped Early:
Combination Treatment Better
- Saquinavir: Major Study Shows Survival
Benefit in Treatment- Naive Patients
- HIV Resistance International
Meeting: Summary on Web; Half- Day Meetings
- National Summit Meeting on HIV Resistance, July 17 -- By Telephone
- AmFAR Will End Support of CBCT Network,
Begin New Clinical Program
- Internet Free Speech Upheld
- AIDS CARE Newsletter
- San Francisco, Healing
Alternatives: Help Wanted, Also Directors, Volunteers
- California: AIDS Hotline Expands to
Cover State, Increases Hours
- Issue #273, June 20, 1997
- FDA Explores New Antiretroviral Trial
Designs: Interview with David Feigal, M.D.
- Protease Inhibitors: FDA Warns Doctors of
Diabetes Risk
- 1592: Protests on Small Access Program
- Help Wanted, Washington D.C.: "Network
Correspondent"
- San Francisco, Oakland: Treatment
Access Workshop, June 27, July 11, July 18
- Issue #272, June 6, 1997
- Limited Immune Recovery After
Treatment with Antiretrovirals, IL-2
Interview with Clifford Lane,
M.D.
- Viral Load in Clinical Trials: FDA
Advisory Committee Meeting July 14-15, 1997
- Meetings Calendar, June 1997 - 1998
- Issue #271, May 16, 1997
- AIDS Treatment News Needs Your Support
- Clinical Trials and Viral Load: Statement
for FDA Community Meeting May 16
- 1592: Small Distribution Programs Begin June, July
- Indinavir (Crixivan(R)) Becoming
Available at Many Pharmacies
- AIDS Internet: Treatment Information
Online
- AIDS News on the World Wide Web: AEGIS (http://www.aegis.com) and Others
- Help Wanted: Project Inform Seeks Hotline Manager
- California: ADAP Program Adds Cidofovir, Nevirapine, and Nelfinavir
- California: Seventh Annual AIDS Lobby Day, June 2
- San Francisco: Lark Lands, Other Experts on Nutrition, Lean Body Mass, & Wasting, June 14
- Issue #270, May 1, 1997
- CMV, RS-79070: Community Concern As Major Drug's Development Suspended
- CMV Retinitis, Newly Diagnosed: RS-79070 Trial
- FDA Community Meeting May 16: Clinical Trials and Viral Load
- HIV Vaccines Need to Be Developed: Interview with Sam Avrett, International AIDS Vaccine Initiative
- 1st National AIDS Malignancy Conference -- Online Summaries Available from April 28-30 Meeting
- Medicaid: AIDS Impact of Proposed Cuts
- Medical Marijuana: Questions Raised on San Francisco Raid
- Issue #269, April 18, 1997
- Delavirdine (Rescriptor(R)) Approved
- Nelfinavir Combination Therapy:
Ten-Month Report
- PMPA -- First Human Results
- Standard Treatments for HIV, Mid 1997
- ADAP Drug-Assistance Programs -- Funding Projections for 1998
- Medicaid: Vice President Gore Supports Early Treatment
- Medical Marijuana Wins Temporary
Restraining Order
- AIDS/HIV TREATMENT DIRECTORY -- Mailing Address
- Meetings Calendar for May 1997
- Issue #268, April 4, 1997
- New AmFAR Directory: Best Quick Reference for Mainstream Treatments
- NAC, Glutamine, and Alpha Lipoic Acid
- Costa Rican PWAs Seek Treatment Access - No Success in Roche Negotiations
- Action Alert: Coburn Bill
- AIDSWATCH '97: Advocacy in Washington, April 13-15
- Issue #267, March 21, 1997
- Ritonavir: New Approval for Children
- HIV InSite: University of California AIDS Web Site
- Acetylcarnitine: Call for Information
- SPV-30: FDA Stops Distribution Over
Advertising
- It's Time to Approve More Surrogate Markers
- AIDS Treatment Activism: Focus on Service
- Issue #266, March 7, 1997
- Stanford NAC Study: Glutathione Level Predicts Survival
- Glutathione-Depleting Drugs: Petition to the FDA
- AIDS Survival: First Drop in Total Deaths in U.S.; Larger Drop in France
- Protease Inhibitors: Major Study Stopped When 3-Drug Arm Proves Superior
- Help Wanted: GMHC Treatment Education Director
- San Francisco: Cattle Grazing, Reservoirs, and Cryptosporidiosis
- Issue #265, February 21, 1997
- Fewer AIDS Deaths and Illnesses: New
Information
- Nelfinavir -- Major Trial Results at
Retroviruses Conference
- DANGER: Possibly Fatal Interactions Between Ritonavir and "Ecstasy," Some Other Psychoactive Drugs
- Free Viral Load Tests Becoming Available for Uninsured Patients
- ABT-378: Abbott "Second Generation" Protease Inhibitor
- Drug-Related Neuropathy: Low Acetylcarnitine Levels Found
- San Francisco: 9th National AIDS Update Conference, March 18-22
- New York: Management of the HIV-Infected
Patient, March 7-9
- New York: ACT UP 10-Year Anniversary: Activist Conference March 22-23, Wall Street Demo March 24
- Retroviruses Conference Information: Tape Sales; Email Access
- Medical Marijuana: New Nationwide Poll Shows 2-1 Public Support
- Medical Marijuana: Followup on THC
Toxicology Report
- Issue #264, February 7, 1997
- Retroviruses Conference Overview:
Consolidating the Advances
- Retroviruses Conference: Where to Get Information
- Low Vitamin B-12 Blood Levels Associated with Faster Progression to AIDS
- Adefovir Dipivoxil: Broad-Spectrum
Antiviral Trial, CD4 Count Under 100
- Opportunistic Infections: Major Report
Available
- Acyclovir-Resistant Herpes: Expanded Access Available for Cidofovir Gel
- Protease Inhibitor Failures: Call for
Information
- Non-Approved Liver Treatments: Call for
Information
- Retroviruses Conference Excludes People with AIDS, Researchers, and Physicians
- Issue #263, January 17, 1997
- 1997 Outlook
- Nelfinavir: Agouron Announces Expanded Access for Children, a Major New Trial, and Enlarged Expanded Access for Adults
- Retroviruses Conference: Where to Find
Reporting on the Internet
- Medical Marijuana: Unpublished Federal Study Found THC-Treated Rats Lived Longer, Had Less Cancer
- Activist Groups and PWA Coalitions, U.S. and Canada
- Issue #262, January 3, 1997
- Hundreds Turned Away from National Retroviruses Conference in January
- Retroviruses Conference: Daily CME Reports Available on World Wide Web
- AIDS Conference Information on the Internet -- How to Present It
- San Francisco: Vocational Counseling
Workshops
1996
- Issue #261, December 20, 1996
- Viral Load Seminars in January and February, Eight U.S. Cities
- d4T+AZT -- Unexpected CD4 Drop Seen in Study
- 1592: Consensus Letter on Access to New Glaxo Drug
- Call for Research on Better Use of Existing Drugs in Advanced Disease
- National Conference on Women and HIV -- Late Breaker Deadline March 21
- Geneva AIDS Conference Seeks Community Planning Coordinator
- Vaccine Report Available
- Reminder: AIDS Treatment News Reader Survey
- Medical Marijuana: Legal Issues for
Physicians and Others
- Marijuana and Research
- AIDS Treatment News 28-Page Index
- AIDS Treatment News Index for 1996
- Issue #260, December 6, 1996
- Buyers' Club Crisis -- Challenge for AIDS
Communities
- Fewer AIDS Deaths: San Francisco Information
- FDA Advisory Committee Deadlocks on Delavirdine
- Albendazole Free from Buyers' Club
- Books: Impure Science
- Buyers' Clubs List, December 1996
- AIDS Treatment News Reader Survey
- Issue #259, November 15, 1996
- Birmingham UK Drug Therapy Conference -- Early Report
- Federal Team Developing Treatment Principles for HIV Infection
- 1592: Two Studies Recruiting
- The New Antiretroviral Arsenal
- Medical Marijuana Wins in California and
Arizona
- FDA Internet Regulation? Public Comment
Accepted until December 16
- AZT Twice-Daily Tablets Approved; Dosing
Concerns
- Retroviruses Conference: Press Deadline
December 6
- Qigong Program on San Francisco KQED TV, Beginning December 7
- Issue #258, November 1, 1996
- HCG: New Kind of KS Treatment?
- IL-2: Controlled Trial Finds Major CD4
Increases
- NTZ for Cryptosporidiosis: Larger Expanded
Access; Buyers' Club/FDA Conflict
- International Treatment Access and Research,
How You Can Help -- Interview with Dr. Peter Piot of UNAIDS
- Retroviruses Conference -- Some Scholarships Available
- Starting and Changing HIV Treatment:
Conference Call Nov. 5, Recording Later
- TREATMENT ISSUES Article on New Therapies After Protease Inhibitors
- AIDSACT, New Email List for Activists
- Hepatitis C: Protease Structure of Virus
Published
- Bioethics: Major Meetings in San Francisco,
November 20-25
- Issue #257, October 18, 1996
- Medical Marijuana: The State of the Research
- Marijuana and Chocolate
- Large Combination Trials with AZT, ddI, ddC: Results Published
- Viral Load Access Consensus Statement
- Viral Load Seminars for Physicians --
Rescheduled
- PhRMA Drops Lawsuit on Government Drug Pricing
- Benefits Planning: What You Must Know (Part II)
- Issue #256, October 4, 1996
- Grassroots Organizing by Internet: An Example
- CKR-5: New Study Confirms Some Do Not Get HIV
- Ritonavir and Saquinavir Combination: 12-Week Data at ICAAC
- Pharmaceutical Industry Sues to Stop Discount Pricing to Clinics
- Congress, Late September 1996: Funding, ADAP, Immigration
- 3TC Clinical Benefit: More Data Presented
- CMV Information: Print, Online, Phone, Video
- Viral Load Seminars for
Physicians: Late October Dates in U.S. Cities
- Viral Load Overview Available from Treatment Action Group
- Washington, October 7: Promoting Treatment and Care in Developing Countries
- Benefits: San Francisco Training, November 1
- Issue #255, September 19, 1996
- Retroviruses Conference Sets January 22-26 1997 Meeting Dates: Abstract Deadline October 16
- Nelfinavir (Viracept) Expanded Access Announced
- ICAAC Conference AIDS Overview -- Available by Toll-Free Phone Call
- Washington AIDS Events: Major Demonstrations October 11, 12, and 13
- Benefits Planning -- What You Must Know:
Interview with Daniel Fortuño, AIDS Benefits Counselors (Part I)
- Issue #254, September 6, 1996
- Human Growth Hormone Approved for Wasting
- ddI plus d4T
- Ritonavir Plus Saquinavir: Two Trials
With Different Results
- CKR-5 -- Understanding the News
- HIV Sensitivity Testing: Organizing for Access
- Register to Vote: Time Running Out
- AIDS Treatment News Associates (ATNA) Receives Nonprofit Status
- Issue #253, August 23, 1996
- Nelfinavir Protease Inhibitor Study Recruiting
- Five-Drug or Six-Drug Antiretroviral Therapy
-- Conversation with Steven Scheibel, M.D.
- 1592 -- New Experimental Antiretroviral
- Medical Marijuana: California Update
- Calendar of AIDS Research and Treatment
Meetings, Late 1996
and Beyond
- Issue #252, August 2, 1996
- Editorial: Time to End the Death Trials
-
3TC: Combination Trial Stopped Early As Clinical
Benefit Shown
- ADAP Treatment-Access Emergency -- Interview
with William
Arnold, ADAP Working Group
- Reminder: Free Viral Load Testing From
Roche, Only Until
August 16
- San Francisco Area: "Highlights from
Vancouver" at Kaiser
Oakland, August 20
- DHEA: Modest Viral Load Reduction in Patients
- San Francisco Cannabis Buyers' Club Raided Aug. 4
- Issue #251, July 19, 1996
- Vancouver in Perspective
- New View of Antiretroviral Treatment:
Illustrations from "Late Breaker" Abstracts
- Expert Panel's New Recommendations for
Antiviral Treatment
- After Vancouver: Documenting Improved
Survival
- Issue #250, July 5, 1996
- Cryptosporidiosis: NTZ at
Buyers' Club; Customs Holds Second Shipment
- NAC: First Controlled Trial, Positive Results
- Nevirapine Approved
- Vancouver Conference: Each Day Summarized
Nightly on World Wide Web
- SCIENCE Publishes Major AIDS Issue June 28;
Full Text on Web
- CMV Retinitis and Treatment: CME Course on
World Wide Web
- Delavirdine Expanded Access Program
Information on World Wide Web
- West Hollywood: AIDS and Chinese Medicine
Conference, July 25-28
- Neuropathy: Nutrient Therapies
- World Wide Web: AIDS Treatment News Lists
Over 100 Sites
- Issue #249, June 21, 1996
- New Optimism on Controlling HIV Infection
- Internet Free Speech Wins Court Test
- Azithromycin Approved for Once-Weekly
MAC Prophylaxis
- Nevirapine Recommended for Approval
- Free Viral Load Tests: Remember to Dial 1
Before 888
- Needlestick Exposure: CDC Recommends
Three-Drug Regimen
- AIDS and Alternative Medicine: A Journalist's
Perspective
- Issue #248, June 7, 1996
- Viral Load Approved; Free Test Offered to All
in U.S. with HIV
- Viral Load: New Recommendations for Clinical
Practice
- Viral Load: New Proof of Importance for
Disease Staging and Prognosis
- Op Ed: Viral Load FDA Approval Delays
- PMPA: New Information
- 3TC: Glaxo Wellcome Broadens Patient
Assistance
- Prison: California Conference on HIV and
Prison Issues, Oakland, June 27
- AIDS Treatment News New Index Available
- Activist Communications, Activities at
Vancouver Conference
- "Access for All": Communication Strategy
Proposal for International Conference
- Issue #247, May 17, 1996
- NIH Scientists Find Cofactor for HIV Entry
- World Medicine and Western Medicine: The
Missing Dialog -- Interview with Kaiya Montaocean, Co-Director, Center for
Natural and Traditional Medicines
- Workshop on Traditional Healing and
Policy, June 13 Near Washington, D.C.
- AIDS Treatment News Back Issues on Web
- Best Internet, Computer Sites on AIDS: Request
for Information
- Computer Communication in Developing
Countries: Request for Information
- AIDS and Media in Developing Countries:
Request for Information
- Pharmaceutical Contributions and
AIDS Organizations: Request for Input
- AIDS Treatment News Policy on
Pharmaceutical-Company Revenue
- Issue #246, May 3, 1996
- Saquinavir: Combination Shows Survival
Benefit; New Formulation Trial Recruiting
- Improved HIV Survival Indicates Effect of
Therapy
- Kaposi's Sarcoma: DaunoXome(R) Approved
- Crixivan(R) Price: Behind the Reduction
- California: 3TC Now Available through
ADAP
- Women and HIV: Conference Calls May 14 and
May 15, on Treatment Concerns
- Alternative Treatments for HIV:
Nationwide Survey Seeks Users
- Federal Policy: Ryan White, OAR, Testing
Newborns
- AIDSWatch 1996: National Lobbying Days in
Washington, May 19-21
- Paris Conference on NAC, Similar Therapeutic
Approaches, May 21-23
- Vancouver Conference Satellite Meetings,
Part II
- Issue #245, April 19, 1996
- Crixivan(R) Price Break for Cash
Customers: $97 Per Month Less, If You Ask
- Protease Inhibitors: Ritonavir and
Saquinavir Combination Trial Recruiting
- Protease Inhibitors: Background
Information
- Delavirdine Available on Expanded
Access
- Sinusitis: Helpful Background, Treatment
Article
- Chinese Medicine: Qigong Exercise Tape
Available
- rGP-160 Treatment Vaccine (VaxSyn):
Canadian Study Finds No Benefit
- FDA Reform in Congress: Interview with Peter
Barton Hutt
- FDA Reform in Congress: FDA's Concerns
- Vancouver Conference: Make Travel Plans
Now. Focus, Program, & Satellite Meetings
- Issue #244, April 5, 1996
- San Francisco: 3TC Available Now to Residents
through ADAP Program
- Protease Inhibitors: Patient Education
Critical
- Indinavir (Crixivan(R)) Access and
Distribution
- AIDS Research at NIH: Study Panel Issues Major
Report
- Viral Load: Inconclusive FDA Hearing
- AZT, ddI, and ddC Combinations at FDA Advisory
Hearing
- Cidofovir Recommended for Approval for
CMV Retinitis
- California: Clinical Trials Computer
Service Now Available Statewide
- San Francisco Protest Against Meeting
Disruptions
- California: AB 2812 Would Outlaw Anonymous
Testing
- AIDS Medications Needed Abroad
- Issue #243, March 15, 1996
- Indinavir (Crixivan(R)), Merck Protease
Inhibitor, Approved
- Ritonavir (NORVIR(TM)), Abbott Protease
Inhibitor, Approved
- Protease Inhibitors at FDA Advisory
Hearings
- FDA Antiviral Hearings: Community Perspectives
- FDA Hearings: For More Information
- Human Growth Hormone Not Recommended for
Approval on Narrow Advisory Panel Vote
- Consensus Statement on the Further
Development of Protease Inhibitors And Human Growth Hormone
- AIDS and Alternative Medicine, Seattle, April
28
- Issue #242, March 1, 1996
- Curcumin: Clinical Trial Finds No
Antiviral Effect
- Protease Inhibitor Approvals -- Will
People Be Cut Off Drug? Followup Studies Proposal Needs Support
- Rolipram: Antidepressant Used in Europe
and Japan Might Have Promise Against TNF, HIV
- Study Finds AIDS Patients Live Longer When
Their Doctors Have More Experience Treating HIV
- Protease Inhibitors at Retroviruses
Conference: Agouron's Results
- Retroviruses Conference: Obtaining
Copies of Abstracts
- DHEA: Threat to Access?
- Issue #241, February, 1996
- Merck Protease Inhibitor: More News from
Retroviruses Conference
- d4T Plus ddI Antiviral Results
- Growing Crisis in Paying for Care
- AB 9: California Bill Would End County Mandate
for Last- Resort Care, Including Communicable Diseases
- Press Gag Rules at AIDS Conference
- Issue #240, February 9, 1996
- Protease Inhibitors at Retroviruses
Conference
- Protease Inhibitors in Human Testing:
Annotated List
- Ritonavir (Abbott Protease Inhibitor)
Proves Survival Benefit in Late-Stage AIDS
- Agouron Starts Phase III Protease Inhibitor
Studies
- Vancouver International Conference:
Community Booths Deadline Extended
- FDA Antiviral Advisory Committee Meetings This
Month
- Prisoners: Send Address Updates;
Contacting Organizations
- NMAC Skills Building Conference in South
Africa: Facilitators Wanted
- Computer Censorship Law, ACLU Test Case,
Begin February 8
- Issue #239, January 19, 1996
- NTZ: Cryptosporidiosis New Treatment
- Viral Load: New Confirmation from Major
Delavirdine Studies
- Protease Inhibitor Update: Treatment
Combination Strategies
- Ritonavir: Expanded Access Begins,
Warning on Drug Interactions
- Stanford NAC Study, San Francisco, Needs
to Contact Screened Applicants and Participants for Followup
- Needle Exchange: Experts Deplore Shalala
Remarks
- Retroviruses Conference Notes
- DHEA and AIDS
- DHEA Clinical Experience: Interview with Jon
Kaiser, M.D.
- Issue #238, January 5, 1996
- Getting Your Insurer to Cover New HIV
Treatments: A Crash Course
- CD8 Cells: Suppressive Factors Discovered
- AZT plus 3TC Combination Results Published
- Opportunistic Infection Prevention: National
Video Symposium January 11
- San Francisco: Cryptosporidiosis Water
Warning
- Computer Censorship Update
- Activist Groups, PWA Coalitions, and Buyers'
Clubs, U.S. and Canada
1995
- Issue #237, December 22, 1995
- Saquinavir (Invirase): First Protease
Inhibitor Approved -- Reimbursement, Info Numbers
- Abbott Protease Inhibitor Lottery in
January, CD4 Under 50 -- Registration Now
- Abbott Protease Inhibitor: Early Results
Reported
- Major Protease Inhibitor Triple
Combination Trial Begins Soon: CD4 Under 200, AZT Experienced, 3TC Naive
- Wasting Syndrome: Oral Oxandrolone
Re-Released in U.S.
- Lymphoma: MGBG New Studies, Compassionate
Use in Earlier Disease
- Human Retroviruses, Immune-Based, and CPCRA
Meetings, Wash. D.C. Late Jan.
- ACTG Clinical Trial Sites: Seven Cut,Two Added
- New York: Protease Inhibitor Forum, January
6
- Computer Censorship: Effect on AIDS
TREATMENT NEWS
- Issue #236, December 1, 1995
- Lamivudine (3TC) Approved for
Combination Use with AZT
- PMPA in Perspective
- DOXIL Approved for KS
- New Double Vs. Triple Antiviral Combination
Study, CD4 200-500, No Prior Treatment
- Internet Censorship: Congress Moves Toward
Final Decision
- Issue #235, November 17, 1995
- Protease Inhibitors: Drug Resistance and
Cross Resistance Overview
- Grapefruit Juice and Saquinavir
- FDA Reform: New Senate Bill
- Issue #234, November 3, 1995
- Thalidomide for Wasting Syndrome:
Progress Toward Compromise
- CMV: Oral Ganciclovir for Prevention
- CMV: New Screening Program
- Cryptosporidiosis Information Phone/Fax Line
- Peptide T: Negative Trial Result
- Issue #233, October 20, 1995
- Viral Load: New "Strategy" Trial in
15 U.S. Cities
- International Conference, Vancouver
1996: Arrangements and Deadlines
- San Francisco Area: Testosterone
Replacement Study, Injection vs. Patch
- Issue #232, October 6, 1995
- Protease Inhibitors and Prevention of
Cross Resistance
- AZT Delta Study: Major European/Australian
Study Finds Combinations Better Than AZT Alone
- Los Angeles, New York, Stanford University:
HBY 097, New Drug May Weaken HIV
- ICAAC's Small Advances
- AIDS Information Obstacles
- Issue #231, September 29, 1995
- ICAAC 1995: New Perspectives on Treatment
- Major Study Shows AZT Monotherapy Inferior
- Abbott Protease Inhibitor In Combination:
Sustained Viral Load Drop
- Agouron Protease Inhibitor
- Saquinavir (Roche Protease Inhibitor) At
Higher Doses
- Ritonavir, Saquinavir Combination -- and
Warning
- Symptom-Reduction Trials at FDA Clinical
Trials Workshop
- Medicaid in Congress: Serious Threat to
Health Care
- Issue #230, September 1, 1995
- Acupuncture and Chinese Medicine;
Interview with Tom Sinclair, L. Ac.
- Hydroxyurea and ddI: French Study
Published
- Thalidomide: New Expanded Access for
Wasting
- Health Insurance: Widespread Copayment
Abuse
- Issue #229, August 18, 1995
- "Confirmatory" Trials: Symptom
Reduction As Efficacy Measure
- FDA Warning on Raw Oysters
- Is NIH AIDS Research in Danger?
- Issue #228, August 4, 1995
- New Antiretroviral Strategies: Interview
with Marcus Conant, M.D.
- 3TC: Now Available Again Up To CD4 of 300
- California: Medi-Cal Can Pay for Human
Growth Hormone for Some Patients
- FDA Reform: Activists' Proposals
|
|
Advertisement
|